AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association (Q33783647)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

gastroenterology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

DiMagno EP

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Reber HA

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Tempero MA

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

1 December 1999

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1464-1484

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The National Cancer Data Base report on pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatitis is a risk factor for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The risk of pancreatic cancer following pancreatitis: An association due to confounding?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Mucinous ductal ectasia of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diabetes and the Risk of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Islet amyloid polypeptide in patients with pancreatic cancer and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Life-style risk factors for pancreatic cancer in Louisiana: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Dietary habits and past medical history as related to fatal pancreas cancer risk among adventists

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diet and pancreatic cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Effects of dietary fish oil (MaxEPA) on N-nitrosobis(2-oxopropyl)amine (BOP)-induced pancreatic carcinogenesis in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Occupation and pancreatic cancer risk in Louisiana

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Vegetables, fruit, and cancer. I. Epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Vegetables, fruit, and cancer. II. Mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic cancer. Assessment of prognosis by clinical presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Factors influencing survival after resection for ductal adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

CA 19-9 serum course and prognosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Elevated serum levels of tumor marker CA19-9 in acute cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Anorexia following the intrahypothalamic administration of amylin

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Ki-ras oncogene activation in preinvasive pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic masses with inconclusive findings on spiral CT: is there a role for MRI?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Endoscopic ultrasound in pancreatic tumor diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Localization of Pancreatic Endocrine Tumors by Endoscopic Ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Endoscopic ultrasonography in diagnosis and staging of pancreatic and biliary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Preoperative staging and assessment of resectability of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Laparoscopy in the management of pancreatic cancer: endoscopic cholecystojejunostomy for advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Laparoscopic biliary and gastric bypass: a useful adjunct in the treatment of carcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Curative Treatment for Pancreatic Neoplasms: Radical Resection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

One hundred and forty-five consecutive pancreaticoduodenectomies without mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Gastric emptying and small bowel transit of solid food after pylorus-preserving pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Long-term evaluation of pylorus preservation during pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Aggressive surgery for pancreatic duct cell cancer: Feasibility, validity, limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radical pancreatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

The Effects of Regionalization on Cost and Outcome for One General High-Risk Surgical Procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Collective review of small carcinomas of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic Cancer Cell DNA Content Correlates With Long-term Survival After Pancreatoduodenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Surgical palliation for pancreatic cancer. The UCLA experience

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Surgical palliation for pancreatic cancer: developments during the past two decades

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of palliative surgical procedures in unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic carcinoma is associated with delayed gastric emptying

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Palliation of malignant gastric outlet obstruction using an endoscopically placed Wallstent

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Expandable metallic prostheses for malignant obstructions of gastric outlet and proximal small bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemical Splanchnicectomy in Patients with Unresectable Pancreatic Cancer A Prospective Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pain and depression in patients with newly diagnosed pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Fate of oral enzymes in pancreatic insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Neoadjuvant therapy for unresectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-d in advanced measurable pancreatic carcinoma.A gastrointestinal tumor study group report

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Treatment of Unresectable Pancreatic Carcinoma with 5-Fluorouracil, Vincristine, and CCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Curative Treatment for Pancreatic Neoplasms: Standard Resection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970298-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0016-5085(99)70298-2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33783647&oldid=1629521500"